CDSCO panel asks Hetero to resubmit Bioequivalence protocol for Trelagliptin Succinate tablet MD Bureau30 Dec 2020 7:12 PM ISTNew Delhi: Noting that the protocol was not scientifically designed and the safety of the study subjects was not taken care of, the Subject Expert...
Hetero launches Favipiravir under brand name of Favivir in India, prices it at Rs 59 per tablet Ruchika Sharma30 July 2020 12:33 PM ISTHyderabad: Pharma giant Hetero has announced the launch of generic Favipiravir in India under the brand name 'Favivir.' Hetero has been...
Cipla, Hetero Labs secure DCGI nod for Remdesivir to treat COVID cases Ruchika Sharma22 Jun 2020 11:01 AM ISTThe drug, administered in the form of injection, should be given at a dose of 200 mg on day one followed by 100 mg daily for five days.
CDSCO reviewing Cipla, Dr Reddys, others applications for Remdesivir on priority: Health Ministry Ruchika Sharma15 Jun 2020 4:00 PM ISTThe CDSCO is awaiting the data and is providing complete support to these companies. It has already waived off the requirement of local clinical...
Cipla, Hetero approach DCGI seeking waiver of Clinical Trial of Remdesivir in India: Report MD Bureau25 May 2020 4:59 PM ISTNew Delhi: With pharma companies across the country making efforts to get the first-mover advantage in bringing potential coronavirus treatments, two...
Hetero ties up with Gilead for Remdesivir Ruchika Sharma14 May 2020 12:16 PM ISTHetero will be supplying Remdesivir in 127 countries, including India, subject to regulatory approvals in respective countries
Hetero gets DCGI approval to market Hepatitis C drug savita thakur thakur9 Dec 2015 11:29 AM ISTNew Delhi: Drug maker Hetero has received approval from DCGI to market generic version of Gilead's Harvoni, a drug used in the treatment of Hepatitis...
Hetero strengthens position in India with launch of biosimilar Rituximab Pooja Bhatia Bhatia4 Aug 2015 1:21 PM ISTHetero has launched the drug under the brand name ‘Maball’ to be used for treatment of certain types of cancers and rheumatoid arthritis Drug firm...
